Results 201 to 210 of about 74,852 (258)

Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib

Cancer, Volume 132, Issue 13, 1 July 2026.
Abstract Background The combination of olaparib plus radium‐223 improved progression‐free survival in patients with metastatic castration‐resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient‐reported outcome (PRO) analysis of this trial is reported.
Rana R. McKay, Wanling Xie, Archana Ajmera, Arlene Araneta, Edmund Folefac, Arif Hussain, Christos E. Kyriakopoulos, Adam Olson, Mamta Parikh, Rahul Parikh, Biren Saraiya, Geoffrey I. Shapiro   +11 more
wiley   +1 more source

APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell. [PDF]

Sci Rep
Rivera M, Liu L, Enlund S, Lim CE, Zhang H, Yang K, Sasik R, Crews LA, Fisch KM, Eskander RN, Holm F, Jiang Q.   +11 more
europepmc   +1 more source

Is a Clinical Trial With a Non‐Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 203-213, July 2026.
Although physiologically based pharmacokinetic (PBPK) modeling is increasingly being used to support oral drug formulation bridging, the acceptance by regulatory agencies is low. One of the primary concerns is the absence of clinical pharmacokinetic (PK) data from a non‐bioequivalent (non‐BE) batch during model validation.
Jin Dong, Andrea Moir, Xavier Pepin, Elizabeth Lowe, Sandy Hopkins, Weifeng Tang, Diansong Zhou   +6 more
wiley   +1 more source

PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape. [PDF]

Cancer Med
Chen Y, Cao J, Huang R, Lou J, Gu J, Luo Z, Yao T, Xie J.   +7 more
europepmc   +1 more source

Pyruvate Kinase M2 Mediates Apigenin‐Induced Energy Crisis and Apoptosis in Colon Cancer Cells

Food Frontiers, Volume 7, Issue 4, July 2026.
Apigenin, a dietary flavonoid with low toxicity, induces profound bioenergetic collapse in colon cancer cells by downregulating PKM2. This metabolic crisis, characterized by suppressed glycolysis and mitochondrial dysfunction, ultimately triggers robust apoptosis.
Ke Zhang, Xingtao Zhou, Xujie Wang, Mingyong Xie   +3 more
wiley   +1 more source

Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis. [PDF]

Front Immunol
Zhang H, Yan G, Yan J, Zeng X.
europepmc   +1 more source

Advances in the Neurotoxic Mechanisms of Acrylamide and Multitarget Intervention Strategies of Natural Products

Food Frontiers, Volume 7, Issue 4, July 2026.
This review summarizes recent advances in acrylamide neurotoxicity mechanisms and highlights the multitarget neuroprotective effects of diverse natural products while also addressing current challenges and future translational research directions.
Wen Du, Yifan Zhao, Li Dong, Chen Ma, Xiaosong Hu, Daotong Li, Fang Chen, Yinghua Luo   +7 more
wiley   +1 more source

PKMYT1 in Cancer: Beyond Cell Cycle Checkpoints to Context‐Dependent Therapeutic Vulnerability

Genes, Chromosomes and Cancer, Volume 65, Issue 7, July 2026.
ABSTRACT PKMYT1 has emerged as a promising therapeutic target distinguished by its tumor‐selective expression and essential role in replication stress management. Unlike WEE1, PKMYT1 is dispensable in normal cell cycles but critical for cancer cells coping with DNA damage, establishing a broad therapeutic window.
Lingxi Li, Binfan He, Mengmeng Hao, Ye Liu, Shunxin Song, Rongzhang He   +5 more
wiley   +1 more source

Metformin Sensitizes PTEN-deficient Prostate Cancer to PARP Inhibitors by Rebuilding NADP⁺ Homeostasis. [PDF]

Int J Biol Sci
Hao X, Chao Z, Peng H, Guo X, Zheng S, Zhang C, Ding H, Wang Y, Xi Z, Gao Y, Qu G, Zhu Y, Chen Z, Lan P, Li L, Wang Z.   +15 more
europepmc   +1 more source

Lessons From Astaxanthin Therapy to Combat Oral Premalignant and Malignant Lesions: A Narrative Review

Health Science Reports, Volume 9, Issue 7, July 2026.
ABSTRACT Background and Aims Oral cancer is one of the most common head and neck malignancies and remains associated with high morbidity, mortality, and treatment‐related toxicity. Despite advances in surgery, radiotherapy, and chemotherapy, there is still a need for safer adjunctive therapies with better therapeutic potential.
Reza Arefnezhad, Zhina Mohamadi, Shervin Shahianjahromi, Amirali Fallahian, Maryam Ashrafi, Armin Nikdehqan, Mitra Saeedi Valashani, Reza Nasiri, Fatemeh Zeinali, Hossein Fatemian, Niloofar Sefati, Fatemeh Rezaei‐Tazangi, Marziye Ranjbar Tavakoli   +12 more
wiley   +1 more source